Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Demetri, George D.; Paz‐Ares, Luis; Farago, Anna F.; Liu, S.V.; Chawla, S.P.; Tosi, Diego; Kim, E.S.; Blakely, C.; Krauss, John C.; Sigal, Darren; Bazhenova, Lyudmila; John, Thomas; Besse, Benjamin; Wolf, Juergen; Seto, Takashi; Chow-Maneval, Edna; Multani, Pratik S.; Johnson, Ann; Simmons, Brian; Doebele, Robert C.

doi:10.1093/annonc/mdy483.003

Cited by 33 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intracranial ORR was 55% in both ROS1-positive NSCLC patients and NTRK fusion-positive solid tumor patients. The median duration of response ranged from 12.6 to 24.6 months [36,37]. DS-6051b is a TKI with high affinity for ROS1 and NTRK kinases/In a phase I/Ib trial, it was found to be well tolerated and had a signal of inhibitory activity.…”

Section: Ntrkmentioning

confidence: 99%

Emerging therapeutic agents for advanced non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first inhuman or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.

show abstract

Section: Ntrkmentioning

confidence: 99%

Emerging therapeutic agents for advanced non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A ROS1 ‐receptor tyrosine kinase gene rearrangement occurs in 1% to 2% of patients who have NSCLC, and approximately 36% of these patients present with BMs. First‐line therapies include crizotinib and ceritinib, and entrectinib recently gained US Food and Drug Administration approval, although evidence of intracranial activity of these agents in this patient population is limited, and CNS‐only disease progression rates on crizotinib are as high as 63% . Patients experiencing CNS disease progression on crizotinib should be considered for upfront BM‐directed therapy.…”

Section: Systemic Treatment Of Brain Metastasesmentioning

confidence: 99%

“…First-line therapies include crizotinib and ceritinib, and entrectinib recently gained US Food and Drug Administration approval, although evidence of intracranial activity of these agents in this patient population is limited, and CNS-only disease progression rates on crizotinib are as high as 63%. 39,40 Patients experiencing CNS disease progression on crizotinib should be considered for upfront BM-directed therapy. In the setting of extensive extracranial disease, however, initiating lorlatinib with close surveillance can be considered because there is evidence of intracranial activity in this setting.…”

Section: Anaplastic Lymphoma Kinase and Ros1 Translocationsmentioning

confidence: 99%

Current multidisciplinary management of brain metastases

Moravan

Fecci

Anders

et al. 2020

Cancer

View full text Add to dashboard Cite

Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late‐stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new and emerging systemic therapies and advancements in radiation oncology and neurosurgery. Current therapies include stereotactic radiosurgery, whole‐brain radiation therapy, surgical resection, laser‐interstitial thermal therapy, systemic cytotoxic chemotherapy, targeted agents, and immune‐checkpoint inhibitors. Determining the optimal treatment for a specific patient has become increasingly individualized, emphasizing the need for multidisciplinary discussions of patients with BM. Recognizing and addressing the sequelae of BMs and their treatment while maintaining quality of life and neurocognition is especially important because survival for patients with BMs has improved. The authors present current and emerging treatment options for patients with BM and suggest approaches for managing sequelae and disease recurrence.

show abstract

“…Tropomyosin receptor kinase (TRK) inhibitors have been reported to be useful for patients with solid tumors harboring neurotrophic receptor tyrosine kinase (NTRK) fusion genes. At the 2018 Annual Meeting of the European Society of Clinical Oncology (ESMO), the results from an integrated analysis of three studies (STARTRK-2 study, STARTRK-1 study and ALKA-372-001 study) conducted in patients with tumors harboring NTRK fusion genes were presented [49]. In these studies, entrectinib, a TRK inhibitor, was administered to 54 patients with soft-tissue sarcomas, non-small cell lung cancer, and others, and the response rate was 57.4%.…”

Section: Chemotherapy For Metastatic Pancreatic Cancermentioning

confidence: 99%

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines

Okusaka¹,

Furuse

2020

J Gastroenterol

View full text Add to dashboard Cite

The prognosis of patients with pancreatic cancer continues to remain dismal, even though numerous trials have been conducted to establish more effective therapies in Japan and throughout the world. Recent advances in treatment have been characterized by the use of novel combinations of conventional cytotoxic chemotherapies. Especially in Japan, S-1 has become one of the most widely used cytotoxic agents for the treatment of pancreatic cancer, after clinical evidence was established of the survival benefit offered by this drug for patients with resectable or unresectable pancreatic cancer. Unfortunately, with the exception of erlotinib, no targeted treatment strategies have been approved for pancreatic cancer. However, following an increase in interest in drug development in recent years, proactive attempts have been made to develop new therapeutic strategies, including neoadjuvant chemotherapy for patients with resectable or borderline resectable pancreatic cancer, multi-agent combination chemotherapy for patients with advanced pancreatic cancer, and therapies with new targeted agents or immunooncologic agents for patients with pancreatic cancer bearing specific gene mutations.

show abstract

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

Abstract: Adverse events were mostly low grade. The most common grade 3 toxicities with olaparib were anaemia (22%) and neutropenia (8%). Olaparib dose reductions, interruptions and discontinuations occurred in 28%, 52% and 12%, respectively. There was no approximately 3 years.

Cited by 33 publications

References 0 publications

Emerging therapeutic agents for advanced non-small cell lung cancer

Emerging therapeutic agents for advanced non-small cell lung cancer

Current multidisciplinary management of brain metastases

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines

Contact Info

Product

Resources

About